种系测序分析为侵袭性前列腺癌的临床基因panel检测提供依据
这项两阶段外显子组测序病例关联研究纳入18项国际研究的欧洲血统男性,比较9185例侵袭性前列腺癌与8361例非侵袭性前列腺癌。BRCA2和ATM罕见有害变异与侵袭性或转移性前列腺癌关联最强(P≤1.9×10⁻⁶),NBN次之(P=1.7×10⁻⁴),MSH2、XRCC2、MRE11A有名义关联(P<.05)。11个候选基因有害变异携带率在非侵袭性、侵袭性和转移性前列腺癌中分别为2.3%、5.6%和7.0%。
要点
- BRCA2和ATM罕见有害变异与侵袭性或转移性前列腺癌关联最强(P≤1.9×10⁻⁶)。
- 11个候选基因有害变异携带率:非侵袭性2.3%、侵袭性5.6%、转移性7.0%。
- TP53、RAD51D、BARD1、GEN1、SLX4风险OR≥2但组间携带频率差异无统计学显著。
核心结论
- 研究结果进一步支持DNA修复和癌症易感基因可用于更好地指导前列腺癌男性的疾病管理,并支持将检测扩展至非侵袭性疾病男性,因为这些基因有害等位基因携带者可能发展为更晚期疾病。
研究设计与样本
- 两阶段外显子组测序病例关联研究,纳入来自18项国际研究的欧洲血统男性,数据分析时间为2021年1月至2023年3月。
- 共纳入17546名欧洲血统男性,包括9185例侵袭性前列腺癌(其中6033例死于前列腺癌、2397例确认转移)和8361例非侵袭性前列腺癌。
- 侵袭性前列腺癌患者诊断时平均(SD)年龄为65.1(9.2)岁,非侵袭性患者为63.7(8.0)岁。
主要发现
- 与侵袭性或转移性前列腺癌关联最强的为已知前列腺癌风险基因BRCA2和ATM的罕见有害变异(P≤1.9×10⁻⁶),其次为NBN(P=1.7×10⁻⁴)。
- MSH2、XRCC2和MRE11A的罕见有害变异与侵袭性前列腺癌存在名义关联(P<.05)。
- TP53、RAD51D、BARD1、GEN1和SLX4共5个基因显示风险增加(OR≥2),但侵袭性与非侵袭性前列腺癌之间的携带频率差异无统计学显著。
- 上述11个候选基因的有害变异携带率在非侵袭性前列腺癌中为2.3%,侵袭性中为5.6%,转移性中为7.0%。
关键数值与推荐
- 主要结局为侵袭性前列腺癌(T4期或T3期且Gleason评分≥8的肿瘤、转移性前列腺癌或前列腺癌死亡)对比非侵袭性前列腺癌(T1或T2期且Gleason评分≤6的肿瘤且无已知复发),以及转移性对比非侵袭性前列腺癌。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Germline gene panel testing is recommended for men with advanced prostate cancer (PCa) or a family history of cancer. While evidence is limited for some genes currently included in panel testing, gene panels are also likely to be incomplete and missing genes that influence PCa risk and aggressive disease. OBJECTIVE: To identify genes associated with aggressive PCa. DESIGN, SETTING, AND PARTICIPANTS: A 2-stage exome sequencing case-only genetic association study was conducted including men of European ancestry from 18 international studies. Data analysis was performed from January 2021 to March 2023. Participants were 9185 men with aggressive PCa (including 6033 who died of PCa and 2397 with confirmed metastasis) and 8361 men with nonaggressive PCa. EXPOSURE: Sequencing data were evaluated exome-wide and in a focused investigation of 29 DNA repair pathway and cancer susceptibility genes, many of which are included on gene panels. MAIN OUTCOMES AND MEASURES: The primary study outcomes were aggressive (category T4 or both T3 and Gleason score ≥8 tumors, metastatic PCa, or PCa death) vs nonaggressive PCa (category T1 or T2 and Gleason score ≤6 tumors without known recurrence), and metastatic vs nonaggressive PCa. RESULTS: A total of 17 546 men of European ancestry were included in the analyses; mean (SD) age at diagnosis was 65.1 (9.2) years in patients with aggressive PCa and 63.7 (8.0) years in those with nonaggressive disease. The strongest evidence of association with aggressive or metastatic PCa was noted for rare deleterious variants in known PCa risk genes BRCA2 and ATM (P ≤ 1.9 × 10-6), followed by NBN (P = 1.7 × 10-4). This study found nominal evidence (P < .05) of association with rare deleterious variants in MSH2, XRCC2, and MRE11A. Five other genes had evidence of greater risk (OR≥2) but carrier frequency differences between aggressive and nonaggressive PCa were not statistically significant: TP53, RAD51D, BARD1, GEN1, and SLX4. Deleterious variants in these 11 candidate genes were carried by 2.3% of patients with nonaggressive, 5.6% with aggressive, and 7.0% with metastatic PCa. CONCLUSIONS AND RELEVANCE: The findings of this study provide further support for DNA repair and cancer susceptibility genes to better inform disease management in men with PCa and for extending testing to men with nonaggressive disease, as men carrying deleterious alleles in these genes are likely to develop more advanced disease.
引用
- Darst BF, Saunders E, Dadaev T, et al. Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer. JAMA Oncol. 2023. PMID: 37733366. doi:10.1001/jamaoncol.2023.3482
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。